Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
15-valent pneumococcal conjugate vaccine is a **multivalent conjugate vaccine candidate** developed in the provided clinical-trial context by Beijing Zhifei Lvzhu Biopharmaceutical for prevention of disease caused by *Streptococcus pneumoniae* serotypes included in the vaccine. It is intended to induce serotype-specific immune responses against pneumococcal capsular antigens and is being clinically evaluated in infants and young children, including primary-series and booster schedules and coadministration with diphtheria, tetanus, and acellular pertussis vaccine. The Zhifei pipeline identifies the program as PCV15 for invasive pneumococcal disease caused by 15 serotypes. ([en.zhifeishengwu.com](https://en.zhifeishengwu.com/about/zfgk))
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on 15-valent pneumococcal conjugate vaccine.